Subscribe to our Newsletters !!
HiMedia Laboratories Pvt Ltd, a leader in Bioscien
Mettler-Toledo Product Inspection has launched the
As there is not one profile that suits all CPAP pa
In its endeavour to fortify its technological capa
IOL Chemicals and Pharmaceuticals Limited (IOL), a
Following the success of the promotion and informa
If you've ever tried to treat your stomachache and
Sun Pharmaceutical Industries Limited announced on Thursday that it would purchase Concert Pharmaceuticals of the United States for $576 million in cash in order to gain access to an investigational medication for the treatment of patchy baldness.
Deuruxolitinib, the top contender for Concert, is being studied as a treatment for the autoimmune disorder alopecia areata, which causes patchy hair loss.
Sun Pharma of India said that it will start a tender offer to buy Concert at $8 per share, a premium of 16% over the stock’s most recent finish.
Additionally, contingent value rights will be given to Concert stockholders, entitling them to an extra sum of up to $3.50 per share of common stock in cash, subject to certain sales milestones.